Topadur Pharma, a clinical-stage biotechnology company specialising in therapies for vascular regeneration, has announced the appointment of Dr Matthias Schäfer as CEO.
Schäfer brings over two decades of experience across the life sciences and healthcare sectors to his new role. His expertise spans research, clinical development, strategic partnerships and portfolio expansion. Schäfer joined Topadur in 2024 as Chief Innovation Officer and Deputy CEO. He has held senior leadership roles at Geistlich Pharma and pfm medical, where he strengthened the company’s global market presence by translating innovation into sustainable commercial growth.
Schäfer will now assist Topadur in further advancing its pipeline towards development and commercialisation.
Dr Reto Naef, the founder of Topadur, will remain on its leadership team in the role of Senior Scientific Advisor, as well as continuing to guide strategy as President of the Board. He commented: “With Matthias stepping into the CEO role, we are ready to accelerate momentum and advance our programs into the next stage.”
Topadur’s lead asset, TOP-N53, is in phase 2a clinical development for treatment of digital ulcers in patients with systemic sclerosis. It has received Orphan Drug Designation from both the US Food and Drug Administration and the European Medicines Agency.
“Topadur is entering an important phase as we advance toward meaningful clinical milestones,” said Schäfer. “Our priorities are progressing our lead programmes in the clinical phases, increasing liquidity and strengthening the organisational capabilities and partnerships needed to support continued growth.”
